Maia Biotechnology shares fall 1.19% intraday after European Patent granted for telomere-targeting anticancer therapy.

Maia Biotechnology, Inc. declined 1.19% in intraday trading, despite the company announcing that the European Patent Office has decided to grant a patent broadly covering a portfolio of eatganosine-based analogues for telomere-targeting anticancer therapy and methods of using eatganosine (THIO) alone or before administration of checkpoint inhibitors (CPIs). The patent, titled 'Mercaptopurine nucleoside Analogues for Altering Telomerase Mediated Telomere,' was invented by MAIA's Chief Scientific Officer Sergei M. Gryaznov, PhD and Scientific Advisory Board member Jerry W. Shay, PhD.